Expected to come online by year end, the "Cambridge-1" system will be an NVIDIA DGX SuperPOD system capable of delivering more than 400 petaflops of AI performance and 8 petaflops of Linpack performance.
Among the first pharmaceutical companies to harness Cambridge-1 for research will be GSK and AstraZeneca. Additionally, researchers from Guy's and St Thomas' NHS Foundation Trust, King's College London and Oxford Nanopore Technologies plan to take advantage of the system.
NVIDIA has previously announced that it intends to create an AI Center of Excellence in Cambridge, featuring a new Arm-based system, which will serve as a hub of collaboration for AI researchers, scientists and startups across the U.K. As these plans develop, Cambridge-1 will become a part of that Center of Excellence, which will expand to include further supercomputers, and support more industries across the U.K.
The system's mission is to support and further enable the U.K. ecosystem of health care and life science researchers, which has become an epicentre for transformative health care research and discovery. Its four key focus areas will be:
1. Joint industry research - Solving large-scale healthcare and data-science problems which otherwise could not be tackled due to their size, resulting in improved patient outcomes, increased success rates and decreased overall healthcare costs.
2. University-granted compute time - Access to NVIDIA GPU time will be donated as a resource to specific studies to contribute to the hunt for cures.
3. Support AI start-ups - NVIDIA will provide opportunities to learn - and it will collaborate with start-ups to nurture the next generation and provide early access to AI tools.
4. Educate future AI practitioners - The system will serve as a destination for world-class researchers and provide hands-on experiences to the next generation.
Cambridge-1 will be the first NVIDIA system designed and built for external research access. Powered by 80 NVIDIA DGX A100 systems connected by NVIDIA Mellanox InfiniBand networking, it will give researchers and academics the ability to tackle some of the most challenging AI training, inference and data science workloads at scale. NVIDIA will invest around GBP 40 million ($51,7 million) in Cambridge-1.
NVIDIA will help researchers take advantage of NVIDIA Clara Discovery, a state-of-the-art suite of tools optimized for NVIDIA DGX that brings together the power of imaging, radiology and genomics to develop AI applications for the biggest computational tasks of health care.
It features pre-trained AI models and application-specific frameworks to help researchers define the next generation of drug discovery processes, from finding targets to building compounds to developing responses.
Using a recent breakthrough in natural language processing, researchers can now leverage biomedical-specific language models to organize, understand and activate large datasets, research literature and sort through papers or patents on existing treatments and other important real-world data.
Top pharmaceutical companies, tech start-ups and members of academia and research plan to use Cambridge-1 for solo and joint projects that expand the boundaries of science - pushing for better patient care, diagnosis and delivery of critical medicines and vaccines around the world.
Each has a vision for modern health care with AI driving wider leaps in existing protocols and practices.
Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, stated: "AI and machine learning are like a new microscope that will help scientists to see things that they couldn't see otherwise. NVIDIA's investment in computing, combined with the power of deep learning, will enable solutions to some of the life sciences industry's greatest challenges and help us continue to deliver transformational medicines and vaccines to patients. Together with GSK's new AI lab in London, I am delighted that these advanced technologies will now be available to help the U.K.s outstanding scientists."